Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Size/SKU | Availability | Price |
|---|
About This Item
eCl@ss:
32160702
UNSPSC Code:
41116100
Pricing and availability is not currently available.
manufacturer/tradename
BPS Bioscience
technique(s)
activity assay: suitable (Fluorescence Polarization)
UniProt accession no.
shipped in
dry ice
storage temp.
-65 to -96°C
General description
The PARPtrap Assay Kit for PARP1 is a fluorescence polarization (FP), homogeneous, 96-well or 384-well assay designed for screening and profiling small molecules that trap PARP1 onto DNA and complex formation in a high throughput screening (HTS) format. The PARPtrap Assay Kit for PARP1 comes in a convenient 96-well or 384-well format, with purified recombinant PARP1 enzyme, a fluorescent-labeled oligonucleotide duplex, NAD+ and PARPtrap assay buffer for 100 or 400 enzyme reactions.
Application
Screen small molecules that enhance PARP1/DNA trapping for drug discovery and high throughput screening (HTS) applications, and IC50 determination.
PARP1, also known as poly-(ADP-ribose) polymerase 1 or NAD+ ADP-ribosyltransferase 1, is part of the PARP family, and it is the most abundant member. ADP ribosylation, which is the addition of an ADP-ribose to a protein, is a reversible post-translational modification of proteins mostly involved in the DNA Damage Response (DDR) pathway. Poly-ADP-ribosylation (termed PARylation) is the addition of linear or branched chains of ADP-ribose. PARP1 participates in DNA repair by non-homologous end joining (NHEJ), homologous recombination (HR), microhomology-mediated end-joining (MMEJ) and nucleotide excision repair. Dysfunction of DDR pathways can lead to oncogenesis. Overexpression of PARP1 has been found in breast and colon cancer, neuroblastoma, and others. This overexpression can lead to increasing MMEJ, an error-prone DNA repair mechanism, and genome instability leading to cancer. In addition to being involved in DDR, PARP1 is also linked to inflammation and type I diabetes. PARP1 is known to bind damaged DNA through its DNA-binding domains. Binding to DNA activates PARP1 and in the presence of NAD+ PARP1 ribosylates itself (auto-ribosylation), what in consequence leads to PARP1 dissociation from the DNA due to the accumulated negative charge of the ribosyl polymer. In the presence of some inhibitors, however, PARP remains bound to DNA, a phenomenon termed trapping. Trapped PARP-DNA complexes have been shown to be highly cytotoxic to cancer cells, therefore such inhibitors may be desirable for cancer treatment. Further understanding of the molecular pathways involving PARP1, and this contribution to disease, will continue to pave the way for new therapies for PARP1-linked diseases.
Datasheet and Protocols for the 96 reaction kit may be found here.
Datasheet an Protocols for the 384 reactoin kit may be found here.
PARP1, also known as poly-(ADP-ribose) polymerase 1 or NAD+ ADP-ribosyltransferase 1, is part of the PARP family, and it is the most abundant member. ADP ribosylation, which is the addition of an ADP-ribose to a protein, is a reversible post-translational modification of proteins mostly involved in the DNA Damage Response (DDR) pathway. Poly-ADP-ribosylation (termed PARylation) is the addition of linear or branched chains of ADP-ribose. PARP1 participates in DNA repair by non-homologous end joining (NHEJ), homologous recombination (HR), microhomology-mediated end-joining (MMEJ) and nucleotide excision repair. Dysfunction of DDR pathways can lead to oncogenesis. Overexpression of PARP1 has been found in breast and colon cancer, neuroblastoma, and others. This overexpression can lead to increasing MMEJ, an error-prone DNA repair mechanism, and genome instability leading to cancer. In addition to being involved in DDR, PARP1 is also linked to inflammation and type I diabetes. PARP1 is known to bind damaged DNA through its DNA-binding domains. Binding to DNA activates PARP1 and in the presence of NAD+ PARP1 ribosylates itself (auto-ribosylation), what in consequence leads to PARP1 dissociation from the DNA due to the accumulated negative charge of the ribosyl polymer. In the presence of some inhibitors, however, PARP remains bound to DNA, a phenomenon termed trapping. Trapped PARP-DNA complexes have been shown to be highly cytotoxic to cancer cells, therefore such inhibitors may be desirable for cancer treatment. Further understanding of the molecular pathways involving PARP1, and this contribution to disease, will continue to pave the way for new therapies for PARP1-linked diseases.
Datasheet and Protocols for the 96 reaction kit may be found here.
Datasheet an Protocols for the 384 reactoin kit may be found here.
1 of 1
This Item | |||
|---|---|---|---|
| description - | description recombinant, expressed in baculovirus infected insect cells, ≥80% (SDS-PAGE) | description Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution | description IgG fraction of antiserum |
| technique(s) activity assay: suitable (Fluorescence Polarization) | technique(s) inhibition assay: suitable | technique(s) immunohistochemistry: 1:500-1:1000, immunoblotting: 0.04-0.4 μg/mL, immunofluorescence: 0.25-2 μg/mL | technique(s) western blot: suitable |
| storage temp. -65 to -96°C | storage temp. −70°C | storage temp. −20°C | storage temp. −20°C |
| manufacturer/tradename BPS Bioscience | manufacturer/tradename Sigma-Aldrich | manufacturer/tradename - | manufacturer/tradename - |
| UniProt accession no. | UniProt accession no. | UniProt accession no. | UniProt accession no. |
| shipped in dry ice | shipped in dry ice | shipped in wet ice | shipped in - |
Storage Class
10 - Combustible liquids
WGK
WGK 1
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.



